Slide 1: Hydreight Technologies FY2025 Results
HYDREIGHT TECHNOLOGIES FY2025 Results Investor Presentation April 2026
Slide 2: Disclaimer & Forward-looking information
Disclaimer & Forward-looking information This presentation and the material contained herein are confidential and are not to be disclosed to the public. This presentation is for information purposes only and may not be reproduced or distributed to any other person or published, in whole or part, for
Slide 3: Disclaimer & Forward-looking information
Disclaimer & Forward-looking information Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including, without limitation, the ability of the C
Slide 4: Hydreight At A Glance
Hydreight At A Glance Hydreight powers digital health brands with comprehensive, compliant, and turnkey infrastructure. Our platform manages the complex legal, clinical, and operational backend – from 50-state compliance to pharmacy fulfillment – enabling brands to scale rapidly in the U.S. market R
Slide 5: 2025 – A Transformational Year of Growth
2025 – A Transformational Year of Growth Quarterly Revenue 14.9 C$ Millions Launch of VSDHOne in mid-2025 VSDHOne Platform marked a growth inflection point Launch in Q3 10.5 Platform continued to accelerate 5.4 in Q4 as additional licenses went live 4.0 4.5 270% revenue growth in Q4 year- 2024 Q4 20
Slide 6: Operating Leverage Already Driving Rising Profitability
Operating Leverage Already Driving Rising Profitability OPEX & OPEX as a % of Revenue Falling C$ Millions 2.8 40% Operating leverage already evident, 35% 36% 2.2 35% even at our current small scale 2.3 1.9 1.9 30% 1.8 1.6 25% 18% H2 2025 OPEX has remained relatively 1.3 15% 20% 15% flat while revenu
Slide 7: 2026 – A Year of Acceleration
2026 – A Year of Acceleration 2026 Revenue Guidance C$ Millions Platform use-case, scalability and $150 operating leverage established in 2025 Clear pathway for 2026 → scaling volumes from existing & new customers $100 Run-Rate Strong first quarter of 2026 and beginning of Q2 Confident in Q1 guidanc
Slide 8: 12,000+ Licenses Signed
Scaling the Platform 12,000+ Licenses Signed as of April 2026, and continuing to grow Majority of licensees yet to be fully onboarded and scaled 8
Slide 9: Multiple Levers Driving Growth Going Forward
Multiple Levers Driving Growth Going Forward VSDHOne Nurse Network M&A Continued Customer New Product & Pharmacy Investments Technology Accelerating Nurse Opportunistic Onboarding & Scaling IP Onboarding / Partnerships Rollout 2.0 Onboarding Acquisitions • Strong pipeline of • Continuing to • Recent
Slide 10: Disciplined Capital Strategy
Disciplined Capital Strategy $15M Fully subscribed + over-allotment exercised Jan 2026 Financing Completed $16M at end of Q4 2025 Cash-On-Hand Growth Investment NCIB / Buybacks Capital deployed into core infrastructure Modest, opportunistic share repurchases Financing new product lines Taking advant
Slide 11: Positioned for 2026
Positioned for 2026 Strong Q1 momentum carrying into Continuing to scale existing licensee Q2 as growth continues to accelerate productivity and engagement Expanding product lines (Peptides, Strong pipeline of new customers GLP-1 + Longevity) currently onboarding Capital deployed into revenue- Risin
Slide 12: Capitalization
Capitalization Capitalization Table LTM Share Price Performance C$ Millions C$ $6.00 $5.00 $4.09 Market Cap $4.00 $236M @ $4.09 $3.00 $1.77 Enterprise Value $196M @ $4.09 $2.00 $1.00 Convertible Notes $12M @ $4.06 - Apr-25 Jul-25 Oct-25 Jan-26 Apr-26 Cash (adj. for Jan capital raise) $30M Ownership
Slide 13: Hydreight Technologies
HYDREIGHT TECHNOLOGIES Email: ir@hydreight.com TSX-V: NURS | OTCQB: HYDTF | FSE: SO6